Showing results (161-170 of 629) with videos related to

Sort By:
Pageof 63
European Heart Journal|September 21, 2022
The search for optimal antithrombotic therapy in transcatheter aortic valve implantation: facts and uncertaintiesJurrien Ten Berg, Bianca Rocca, Dominick J Angiolillo, et al.
European Heart Journal|February 6, 2016
A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized studyFabiana Rollini, Francesco Franchi, Jung Rae Cho, et al.
Thrombosis and Haemostasis|May 24, 2023
Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) StudyLuis Ortega-Paz, Francesco Franchi, Fabiana Rollini, et al.
Journal of Thrombosis and Thrombolysis|May 25, 2025
Antiplatelet therapy following conservatively managed spontaneous coronary artery dissectionMadeline K Mahowald, Luis Ortega-Paz, Claudio Laudani, et al.
British Journal of Clinical Pharmacology|September 13, 2011
Antiplatelet therapy: thrombin receptor antagonistsAntonio Tello-Montoliu, Salvatore D Tomasello, Masafumi Ueno, et al.
Expert Opinion on Investigational Drugs|May 13, 2020
Selatogrel, a novel P2Y12 inhibitor: a review of the pharmacology and clinical developmentRocco P Milluzzo, Gabriele A Franchina, Davide Capodanno, et al.
Expert Opinion on Drug Safety|September 19, 2018
Gender differences on benefits and risks associated with oral antithrombotic medications for coronary artery diseaseSara Romano, Sergio Buccheri, Roxana Mehran, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|April 2, 2025
Chronic Coronary Syndrome and New-Onset Atrial Fibrillation or Venous Thromboembolism: How Best to Manage Antithrombotic Therapy StrategiesAndrea Rubboli, Dominick J Angiolillo, Cecilia Becattini, et al.
Clinical Therapeutics|November 15, 2011
Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trialDominick J Angiolillo, Clara Hwang, Catherine Datto, et al.
Expert Opinion on Drug Safety|November 12, 2020
Safety and efficacy of P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary interventionsMattia Galli, Davide Capodanno, Felicita Andreotti, et al.
Pageof 63